Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Solid Biosciences Inc | SLDB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 9.04 | 07:00:04 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 9.04 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.81 - 15.05 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 9.04 | USD |
Solid Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 341.32M | 37.76M | - | 0 | -96.02M | -2.54 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Solid Biosciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SLDB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 9.94 | 10.18 | 8.54 | 9.44 | 163,288 | -0.90 | -9.05% |
| 1 Month | 13.74 | 15.05 | 8.54 | 11.84 | 219,433 | -4.70 | -34.21% |
| 3 Months | 7.94 | 15.05 | 5.40 | 10.87 | 268,597 | 1.10 | 13.85% |
| 6 Months | 2.15 | 15.05 | 1.81 | 6.45 | 453,793 | 6.89 | 320.47% |
| 1 Year | 4.86 | 15.05 | 1.81 | 6.36 | 239,018 | 4.18 | 86.01% |
| 3 Years | 74.25 | 81.90 | 1.81 | 25.76 | 551,995 | -65.21 | -87.82% |
| 5 Years | 135.45 | 203.70 | 1.81 | 55.47 | 861,535 | -126.41 | -93.33% |
Solid Biosciences Description
| Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of speciality and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. Its lead product candidate, the SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices. |
